Terms: = Lung cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Clinical Outcome
19 results:
1. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse outcomes in Patients With EGFR-Mutant lung cancer.
Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
[TBL] [Abstract] [Full Text] [Related]
2. Synchronous lung and multiple soft tissue metastases developed from osteosarcoma of tibia: a rare case report and genetic profile analysis.
Zheng C; Wang Y; Luo Y; Pang Z; Zhou Y; Min L; Tu C
BMC Musculoskelet Disord; 2022 Jan; 23(1):74. PubMed ID: 35057767
[TBL] [Abstract] [Full Text] [Related]
3. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
[TBL] [Abstract] [Full Text] [Related]
4. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
Owonikoko TK; Niu H; Nackaerts K; Csoszi T; Ostoros G; Mark Z; Baik C; Joy AA; Chouaid C; Jaime JC; Kolek V; Majem M; Roubec J; Santos ES; Chiang AC; Speranza G; Belani CP; Chiappori A; Patel MR; Czebe K; Byers L; Bahamon B; Li C; Sheldon-Waniga E; Kong EF; Williams M; Badola S; Shin H; Bedford L; Ecsedy JA; Bryant M; Jones S; Simmons J; Leonard EJ; Ullmann CD; Spigel DR;
J Thorac Oncol; 2020 Feb; 15(2):274-287. PubMed ID: 31655296
[TBL] [Abstract] [Full Text] [Related]
5. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
[TBL] [Abstract] [Full Text] [Related]
6. Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on clinical outcomes in East-Asian Patients with EGFR-Mutated lung Adenocarcinoma.
Sato S; Nagahashi M; Koike T; Ichikawa H; Shimada Y; Watanabe S; Kikuchi T; Takada K; Nakanishi R; Oki E; Okamoto T; Akazawa K; Lyle S; Ling Y; Takabe K; Okuda S; Wakai T; Tsuchida M
Sci Rep; 2018 Jan; 8(1):1005. PubMed ID: 29343775
[TBL] [Abstract] [Full Text] [Related]
7. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Choi M; Kadara H; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Kim K; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Herbst RS; Wistuba II
Ann Oncol; 2017 Jan; 28(1):83-89. PubMed ID: 28177435
[TBL] [Abstract] [Full Text] [Related]
8. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.
Ohmoto A; Rokutan H; Yachida S
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098761
[TBL] [Abstract] [Full Text] [Related]
9. PSAT1 regulates cyclin D1 degradation and sustains proliferation of non-small cell lung cancer cells.
Yang Y; Wu J; Cai J; He Z; Yuan J; Zhu X; Li Y; Li M; Guan H
Int J Cancer; 2015 Feb; 136(4):E39-50. PubMed ID: 25142862
[TBL] [Abstract] [Full Text] [Related]
10. The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses.
Salinas-Souza C; De Oliveira R; Alves MT; Garcia Filho RJ; Petrilli AS; Toledo SR
Hum Pathol; 2013 Oct; 44(10):2188-98. PubMed ID: 23845465
[TBL] [Abstract] [Full Text] [Related]
11. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.
Nanjundan M; Byers LA; Carey MS; Siwak DR; Raso MG; Diao L; Wang J; Coombes KR; Roth JA; Mills GB; Wistuba II; Minna JD; Heymach JV
J Thorac Oncol; 2010 Dec; 5(12):1894-904. PubMed ID: 21124077
[TBL] [Abstract] [Full Text] [Related]
12. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors.
Igarashi T; Jiang SX; Kameya T; Asamura H; Sato Y; Nagai K; Okayasu I
Mod Pathol; 2004 Oct; 17(10):1259-67. PubMed ID: 15154011
[TBL] [Abstract] [Full Text] [Related]
13. Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers.
Hommura F; Dosaka-Akita H; Kinoshita I; Mishina T; Hiroumi H; Ogura S; Katoh H; Kawakami Y
Br J Cancer; 1999 Oct; 81(4):696-701. PubMed ID: 10574258
[TBL] [Abstract] [Full Text] [Related]
14. Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome.
Mishina T; Dosaka-Akita H; Kinoshita I; Hommura F; Morikawa T; Katoh H; Kawakami Y
Br J Cancer; 1999 Jun; 80(8):1289-95. PubMed ID: 10376986
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers.
Nishio M; Koshikawa T; Yatabe Y; Kuroishi T; Suyama M; Nagatake M; Sugiura T; Ariyoshi Y; Mitsudomi T; Takahashi T
Clin Cancer Res; 1997 Jul; 3(7):1051-8. PubMed ID: 9815783
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic factors in resected non-small cell lung cancer: an immunohistochemical study of 39 cases.
Kwa HB; Verheijen MG; Litvinov SV; Dijkman JH; Mooi WJ; Van Krieken JH
Lung Cancer; 1996 Dec; 16(1):35-45. PubMed ID: 9017583
[TBL] [Abstract] [Full Text] [Related]
17. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma.
Shimizu E; Coxon A; Otterson GA; Steinberg SM; Kratzke RA; Kim YW; Fedorko J; Oie H; Johnson BE; Mulshine JL
Oncogene; 1994 Sep; 9(9):2441-8. PubMed ID: 8058306
[TBL] [Abstract] [Full Text] [Related]
18. Mutation spectrum of the retinoblastoma gene in osteosarcomas.
Wadayama B; Toguchida J; Shimizu T; Ishizaki K; Sasaki MS; Kotoura Y; Yamamuro T
Cancer Res; 1994 Jun; 54(11):3042-8. PubMed ID: 8187094
[TBL] [Abstract] [Full Text] [Related]
19. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer.
Cordon-Cardo C; Wartinger D; Petrylak D; Dalbagni G; Fair WR; Fuks Z; Reuter VE
J Natl Cancer Inst; 1992 Aug; 84(16):1251-6. PubMed ID: 1640484
[TBL] [Abstract] [Full Text] [Related]
